Current Research Status Of The TACE Treatment For Primary Liver Cancer

Primary liver cancer is one of the most common malignant cancers in the world,which ranks the sixth in the morbidity of malignant cancers and the third in the death rate of cancer related illnesses.China is one of the countries that has the most liver cancer patients and HBV carriers,85%-90% of the liver cancer is generated on the basis of cirrhosis after patients getting hepatitis,and the annual new case of liver cancer in China accounts for more than 50% of that of the world.The death rate of liver cancer ranks only second to lung cancer and even ranks first in some high-prevalence rural areas.Surgery is considered the optimal treatment for liver cancer,however,liver cancer is imperceptible and develops quickly,and it generally belongs to the interim or the terminal stage when diagnosed.Besides,liver cancer patients sometimes lose the chance of undergoing surgery in that they usually have poor hepatic functional reserve,intrahepatic metastasis and vascular invasion,so other treatment methods are needed in this situation.Since the TACE was proposed in 1978,it has been widely used.And the mainstream treatment status of TACE for midterm liver cancer was established with the Barcelona Clinic Liver Cancer came into existence.It has been proved through research that TACE treatment can improve the quality of life and life span of patients with liver cancer.With the constant appearance of multi-mode interventional therapies in clinical practice,the interventional therapy,especially TACE,makes certain progress in the treating of liver cancer.The article summarizes the research status of the TACE treatment for liver cancer as follows with the hope of enlightening the selection of clinical treatment for liver cancer.